Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.68 |
| ▸ | CA2 | P00918 | 3/20 | 0.68 |
| ▸ | CA9 | Q16790 | 2/20 | 0.68 |
| ▸ | CA12 | O43570 | 2/20 | 0.68 |
| ▸ | CA7 | P43166 | 2/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | CA6 | P23280 | 1/20 | 0.68 |
| ▸ | CA5A | P35218 | 1/20 | 0.68 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | NT5E | P21589 | 3/20 | 0.50 |
| ▸ | CASP6 | P55212 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14471903 | 0.83 | ALDH1A1 (0.62) | CA1CA2CA9CA12CA7 | |
| SCHEMBL3072708 | 0.83 | HSD17B10 (0.51) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2807669 | 0.83 | CA1 (0.73) | CA1CA2CA9CA12CA7 | |
| SCHEMBL30291161 | 0.81 | CA2 (1.00) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1179872 | 0.81 | CA2 (1.00) | CA1CA2CA9CA12CA7 | |
| SCHEMBL31618973 | 0.81 | CA1 (0.70) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1979458 | 0.80 | TDP1 (0.48) | CA1CA2CA9CA12CA7 | |
| SCHEMBL391971 | 0.80 | ALDH1A1 (0.69) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2778156 | 0.79 | CA1 (0.68) | CA1CA2CA9CA12CA7 | |
| SCHEMBL221279 | 0.79 | CA1 (0.68) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024221045-A1 | IMMUNOGENIC COMPOSITION | GRIFFITH UNIVERSITY (AU) | 2024-10-31 | — | — | WO | disclosed |
| EP-3581617-A1 | COMPOSITIONS COMPRISING A FILM-FORMING POLYMER AND AN AROMATIC ACID OR SALT THEREOF, AND PREPARATION AND USES THEREOF | Synthomer (UK) Ltd. (GB) | 2019-12-18 | — | — | EP | disclosed |
| EP-1064274-B1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| WO-2004049914-A2 | METHODS FOR REACTING AN ANTIGEN MASKING COMPOUND WITH RED BLOOD CELLS WITH HIGH EFFICIENCY | CERUS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050897-A2 | METHODS FOR PREPARING ANTIGEN MASKED RED BLOOD CELLS HAVING REDUCED HEMOLYSIS BY SERA | CERUS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050848-A2 | METHODS FOR ANTIGEN MASKING OF RED BLOOD CELLS RESULTING IN REDUCED HEMOLYSIS | CERUS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| US-6667342-B1 | Elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2003-12-23 | — | — | US | disclosed |
| US-20030207247-A1 | Preparation of red blood cells having reduced immunogenicity | CERUS CORPORATION (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003047650-A2 | PREPARATION OF RED BLOOD CELLS HAVING REDUCED IMMUNOGENICITY | CERUS CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1284743-A2 | PREPARATION OF A PATHOGEN INACTIVATED SOLUTION OF RED BLOOD CELLS HAVING REDUCED IMMUNOGENICITY | Cerus Corporation (US) | 2003-02-26 | — | — | EP | disclosed |
| WO-2001091775-A2 | PREPARATION OF A PATHOGEN INACTIVATED SOLUTION OF RED BLOOD CELLS HAVING REDUCED IMMUNOGENICITY | CERUS CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
| CN-1293666-A | Phenylthioamide derivatives and their use as pharmaceuticals | ASTRA ZENECA LTD (SE) | 2001-05-02 | — | — | CN | disclosed |
| EP-0921817-B1 | PEGYLATION PROCESS | POLYMASC PHARMACEUTICALS PLC (GB) | 2001-03-28 | — | — | EP | disclosed |
| EP-1064274-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEDICAMENTS | AstraZeneca AB (SE) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047508-A1 | BENZENESULFONAMIDE-DERIVATIVES AND THEIR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 1999-09-23 | — | — | WO | disclosed |
| EP-0921817-A1 | PEGYLATION PROCESS | PolyMASC Pharmaceuticals plc (GB) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998032466-A1 | PEGYLATION PROCESS | POLYMASC PHARMACEUTICALS PLC (GB) | 1998-07-30 | — | — | WO | disclosed |
| US-4801693-A | DYEING WOOL, CELLULOSE, OR COTTON | BASF AKTIENGESELLSCHAFT (DE) | 1989-01-31 | — | — | US | disclosed |
| EP-0167785-B1 | REACTIVE DYES | BASF Aktiengesellschaft (DE) | 1988-08-03 | — | — | EP | disclosed |
| EP-0167785-A1 | Reactive dyes | BASF Aktiengesellschaft (DE) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207247-A1 | Preparation of red blood cells having reduced immunogenicity | CD47, HLA-C, HLA-B | CA1 489/4885CA2 1519/4885CA9 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.